GNI Group Ltd. (2160.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
GNI Group Ltd.
Address
Nihonbashi-Honcho YS Building
Tokyo, 103-0023
Japan
Phone
81 3 6214 3600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
867
First IPO Date
August 31, 2007
Key Executives
| Name | Title | Pay | Year Born |
| Ying Luo | Chief Executive Officer, President, Representative Executive Officer & Chair | 76M | 1965 |
| Zhang Ping | Executive Officer & Director | 49M | 1973 |
| Kazuhiro Kawauchi | Executive Officer & Chief Business Development Officer | 0 | 1962 |
| Cristin Print | Co-Founder | 0 | N/A |
| Stephen Charnock-Jones | Co-Founder | 0 | N/A |
| Takuya Kaneko | Executive Officer, CSO, GM of Administration Div, Head of Grp Alliance Prom Office | 0 | N/A |
| Kosuke Tashiro | Co-Founder | 0 | N/A |
| Ryosuke Matsui | Executive Officer, VP, COO, CFO & Director | 0 | 1979 |
| Kan-ichiro Suzuki | Vice President & Executive Officer | 0 | 1954 |
Description
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
